Trial Profile

Concurrent Nimotuzumab and Intensity-modulated Radiotherapy for Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nimotuzumab (Primary) ; Ropidoxuridine
Indications Carcinoma; Nasopharyngeal cancer
Focus Adverse reactions

Most Recent Events

01 Aug 2024 Results assessing the efficacy of concurrent nimotuzumab combined with intensity-modulated radiotherapy (IMRT) in elderly patients with locally advanced NPC published in the Cancer Science
02 May 2024 Status changed from recruiting to completed.
31 May 2019 Results assessing safety and efficacy of nimotuzumab and IMRT in patients with nasophyaryngeal carcinoma, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com